本文選題：脊髓灰質(zhì)炎減毒活疫苗 + 脊髓灰質(zhì)炎滅活疫苗��； 參考：《中國(guó)疫苗和免疫》2017年05期

【摘要】：目的比較分析河北省脊髓灰質(zhì)炎(脊灰)疫苗預(yù)防接種的安全性。方法收集河北省2015年5-10月三價(jià)脊灰減毒活疫苗(tOPV)、脊灰滅活疫苗(IPV)和2016年同期二價(jià)脊灰減毒活疫苗(bOPV)、IPV的疑似預(yù)防接種異常反應(yīng)(AEFI)監(jiān)測(cè)數(shù)據(jù),比較分析各疫苗AEFI報(bào)告發(fā)生率。結(jié)果河北省2015年5-10月tOPV、IPV的AEFI報(bào)告發(fā)生率分別為5.64/10萬(wàn)、35.96/10萬(wàn);2016年同期bOPV、IPV的AEFI報(bào)告發(fā)生率分別為16.06/10萬(wàn)、17.85/10萬(wàn)。各疫苗AEFI均以≤1歲年齡組、一般反應(yīng)為主,主要發(fā)生在接種疫苗后≤48h。結(jié)論河北省各脊灰疫苗預(yù)防接種安全性良好,bOPV的AEFI報(bào)告發(fā)生率高于tOPV,需進(jìn)一步加強(qiáng)脊灰疫苗安全性監(jiān)測(cè)。
[Abstract]:Objective to compare and analyze the safety of polio vaccination in Hebei province. Methods the surveillance data of suspected abnormal vaccination response (AEFIe) of live attenuated poliomyelitis vaccine (AEFI) in Hebei province from May to October 2015 and bivalent live attenuated polio vaccine from 2016 were collected, and the reported incidence of AEFI was compared and analyzed. Results from May to October 2015, the incidence of AEFI reporting of tOPV-IPV in Hebei Province was 564 / 100 000 or 359.6 / 100 000, respectively, and the incidence rate of AEFI reporting of AEFI in the same period of 2016 was 16.06 / 100 000 or 17.85% / 100 000 respectively. The AEFI of each vaccine was mainly in the age group of 鈮，

本文編號(hào)：1943070